Ranbaxy launches sugar free chyawanprash  “Chawan Active”

Ranbaxy Laboratories has entered into the Chyawanprash segment by launching its sugar-free product under the brand name 'Chyawan Active'. It is an Ayurvedic Proprietary Medicine developed by the company's Herbal Drug Research team. The product has been manufactured using a novel formulation technology that not only preserves all the benefits of classical ayurvedic chyawanprash, but also ensures a great taste, without any added sugar.

Traditional Chyawanprash contains almost 50-60 per cent added sugar.  Ranbaxy's 'Chyawan Active' does not have any added sugar, thereby making it a healthy, low calorie alternative for the existing consumers of Chyawanprash.

It is estimated that India houses more than 40 million diabetic patients; has a male population of over 12 per cent and a female population of above 16 per cent in the obese/overweight category. This phenomenon is alarmingly being witnessed amongst children & adolescents as well.

The product marketed by Ranbaxy's Global Consumer Healthcare division, will be initially introduced in North India (Delhi, UP, Punjab and Bihar) and later in other parts of the country.

The Chyawanprash segment has a market size of around Rs. 250 crores and saw a growth of more than 15% in value and volume terms in 2006-07. Innovations are likely to drive the market, which still has a low market penetration of about 4 %. The sugar-free products market estimated to be around Rs 300-400 crore is growing at rate of 25%. The Chyawanprash market, which was earlier languishing, has shown a 19.5% growth in 2006-07, as against a mere 2.6% growth in 2005-06, according to AC Nielsen. Recently, Dabur introduced a chocolate-flavoured granular variant of Dabur Chyawanprash for children.

Ranbaxy Global Consumer Healthcare (RGCH) was established in October 2002 with an objective to promote OTC healthcare brands to consumers. Today it has some of the top selling brands with leadership status in its segment. The major brands from RGCH include Volini (pain relieving gel), Chericof (cough syrup) & Pepfiz (digestive).

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.